School of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
Division of Urologic Oncology, Department of Urology, NYU Langone Health, New York City, New York, USA.
Int J Urol. 2022 Aug;29(8):845-851. doi: 10.1111/iju.14910. Epub 2022 Apr 26.
We sought to assess if adding a biopsy proven histologic subtype to a model that predicts overall survival that includes variables representing competing risks in observed, biopsy proven, T1a renal cell carcinomas, enhances the model's performance.
The National Cancer Database was assessed (years 2004-2015) for patients with observed T1a renal cell carcinoma who had undergone renal mass biopsy. Kaplan-Meier curves were utilized to estimate overall survival stratified by histologic subtype. We utilized C-index from a Cox proportional hazards model to evaluate the impact of adding histologic subtypes to a model to predict overall survival for each stage.
Of 132 958 T1a renal masses identified, 1614 had biopsy proven histology and were managed non-operatively. Of those, 61% were clear cell, 33% papillary, and 6% chromophobe. Adjusted Kaplan-Meier curves demonstrated a difference in overall survival between histologic subtypes (P = 0.010) with greater median overall survival for patients with chromophobe (85.1 months, hazard rate 0.45, P = 0.005) compared to clear cell (64.8 months, reference group). Adding histology to a model with competing risks alone did not substantially improve model performance (C-index 0.65 vs 0.64 respectively).
Incorporation of histologic subtype into a risk stratification model to determine prognostic overall survival did not improve modeling of overall survival compared with variables representing competing risks in patients with T1a renal cell carcinoma managed with observation. These results suggest that performing renal mass biopsy in order to obtain tumor histology may have limited utility. Future studies should further investigate the overall utility of renal mass biopsy for observed T1a kidney cancers.
我们旨在评估在包含观察性、经活检证实的 T1a 肾细胞癌中代表竞争风险的变量的模型中添加组织学亚型是否可以提高预测总生存期的模型性能。
评估国家癌症数据库(2004-2015 年)中接受过肾肿块活检的观察性 T1a 肾细胞癌患者。Kaplan-Meier 曲线用于估计按组织学亚型分层的总生存期。我们利用 Cox 比例风险模型的 C 指数评估将组织学亚型添加到预测每个分期总生存期的模型中的影响。
在 132958 个 T1a 肾肿块中,有 1614 个经活检证实为组织学,并进行了非手术治疗。其中,61%为透明细胞癌,33%为乳头状癌,6%为嫌色细胞癌。调整后的 Kaplan-Meier 曲线显示组织学亚型之间的总生存期存在差异(P=0.010),与透明细胞癌(中位总生存期 64.8 个月,参考组)相比,嫌色细胞癌(中位总生存期 85.1 个月,危险比 0.45,P=0.005)的总生存期更长。仅将组织学添加到具有竞争风险的模型中并不能显著提高模型性能(C 指数分别为 0.65 和 0.64)。
在 T1a 肾细胞癌患者中,将组织学亚型纳入风险分层模型以确定预测总生存期的预后与代表竞争风险的变量相比,并不能改善总生存期的建模。这些结果表明,为了获得肿瘤组织学而进行肾肿块活检可能具有有限的实用性。未来的研究应进一步探讨观察性 T1a 肾癌进行肾肿块活检的整体效用。